[1] Rebhandl W, Rami B, Turbull J, et al. Diagnostic value of tissue polypeptide-specific antigen (TPS) in neuroblastoma and Willms' tumour[J].Br J Cancer,1998,78(11): 1503-1506.
[2] Senapad S, Neungton S, Thirapakawong C, et al. Predictive calue of the combined serum CA125 and TPS during chemotherapy and before second-look laparotomy in epithelial ovarian cancer[J]. Anticancer Res, 2000, 20(2B): 1297-1300.
[3] Van Dalen A, Favier J, Baumgartner L, et al. Prognostic significance of CA125 and TPS levels after chemotherapy in ovarian cancer atients[J]. Anticancer Res, 1999, 19(4A): 2523-2526.
[4] Tempfer C, Hefler L, Haeusler G, et al. Tissue polypeptide specific antigen in the follow-up of ovarian and cervical cancer patients[J]. Int J Cancer, 1998, 79(3): 241-244.
[5] Nisman B, Lafair J, Heching N, et al. Evaluation of tissue polypeptide specific antigen, CYFRA21-1 and carcinoem-bryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?[J]. Cancer, 1998, 82(10): 1850-1859.
[6] Ho YJ, Hsieh JF, Tasi SC, et al. Tissue polypeptide specific antigen and squamous cell carcinoma antigen for early prediction of recurrence in lung squamous cell carcinoma[J]. Lung, 2000, 178(2): 75-80.
[7] Slesak B, Harlozinska-Szmyrka A, Knast W, et al. Tissue polyopeptide specific antigen(TPS), a amrker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative studywith CA19-9[J]. Cancer, 2000, 89(1): 83-88.
[8] Polito M, Minardi D, Recchioni A, et al. Serum markers for monitoring of prostatic carcinoma[J]. Prostate, 1997, 33(3): 208-216.
[9] Suzuki S, Furukawa H, Tsuchiya A, et al. Clinical evaluation of serum tissue polypeptide specific antigen in patients with thyroid carcinoma[J]. Thyroid, 1999, 9(9): 921-925.